PMID- 23816920
OWN - NLM
STAT- MEDLINE
DCOM- 20131112
LR  - 20220325
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 162
IP  - 1
DP  - 2013
TI  - Immunologic effects of omalizumab in children with severe refractory atopic 
      dermatitis: a randomized, placebo-controlled clinical trial.
PG  - 89-93
LID - 10.1159/000350486 [doi]
AB  - BACKGROUND: Severe refractory atopic dermatitis (AD) is a chronic, debilitating 
      condition that is associated with elevated serum immunoglobulin E (IgE) levels. 
      Thymic stromal lymphopoietin (TSLP), thymus and activation-regulated chemokine 
      (TARC) and OX40 ligand (OX40L) are important immunologic factors involved in the 
      pathogenesis of AD. Omalizumab, an anti-IgE antibody indicated for use in 
      allergic asthma, is implicated in regulating allergen presentation by dendritic 
      cells and the T cell response during the effector phases of allergic disease. We 
      investigated if anti-IgE therapy modulates the allergen-specific responses 
      mediated by the TSLP pathway in young patients with severe refractory AD. 
      METHODS: This was a randomized, double-blind, placebo-controlled study of 8 
      patients between the ages of 4 and 22 years (mean = 11.6 years) with severe 
      refractory AD (clinical trials.gov NCT01678092). Serum IgE ranged from 218 to 
      1,890 (mean = 1,068 IU/ml). Subjects received omalizumab (n = 4) or placebo (n = 
      4) every 2-4 weeks over 24 weeks using a regimen extrapolated from the package 
      insert. TSLP, TARC, OX40L and other cytokines involved in AD were measured by 
      using cytometric bead arrays. RESULTS: All patients receiving omalizumab had 
      strikingly decreased levels of TSLP, OX40L, TARC (involved in Th2 polarization) 
      and interleukin (IL)-9 compared to placebo. In addition, there was a marked 
      increase in IL-10, a tolerogenic cytokine, in the omalizumab-treated group. 
      Patients on anti-IgE therapy had an improvement in clinical outcomes as measured 
      by the SCORAD system; however, these effects were comparable to improvements in 
      the control group. CONCLUSIONS: Anti-IgE therapy with omalizumab decreases levels 
      of cytokines that are involved in Th2 polarization and allergic inflammation, 
      including TSLP, TARC and OX40L.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Iyengar, Shuba Rajashri
AU  - Iyengar SR
AD  - Division of Pediatric Allergy, Massachusetts General Hospital, Boston, Mass., 
      USA.
FAU - Hoyte, Elizabeth G
AU  - Hoyte EG
FAU - Loza, Angelica
AU  - Loza A
FAU - Bonaccorso, Salvatore
AU  - Bonaccorso S
FAU - Chiang, David
AU  - Chiang D
FAU - Umetsu, Dale T
AU  - Umetsu DT
FAU - Nadeau, Kari Christine
AU  - Nadeau KC
LA  - eng
SI  - ClinicalTrials.gov/NCT01678092
GR  - R21 AI095838/AI/NIAID NIH HHS/United States
GR  - U01 AI147462/AI/NIAID NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130627
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Cytokines)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cytokines/blood
MH  - Dermatitis, Atopic/*drug therapy/immunology
MH  - Double-Blind Method
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Omalizumab
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4161454
MID - NIHMS606204
EDAT- 2013/07/03 06:00
MHDA- 2013/11/13 06:00
PMCR- 2014/09/11
CRDT- 2013/07/03 06:00
PHST- 2012/11/19 00:00 [received]
PHST- 2013/03/01 00:00 [accepted]
PHST- 2013/07/03 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2013/11/13 06:00 [medline]
PHST- 2014/09/11 00:00 [pmc-release]
AID - 000350486 [pii]
AID - 10.1159/000350486 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2013;162(1):89-93. doi: 10.1159/000350486. Epub 2013 
      Jun 27.